Capstone Capital LLC Takes $265,000 Position in Eli Lilly and Company (NYSE:LLY)

Capstone Capital LLC purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 341 shares of the company’s stock, valued at approximately $265,000. Eli Lilly and Company accounts for 0.2% of Capstone Capital LLC’s portfolio, making the stock its 16th biggest holding.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of Eli Lilly and Company during the 4th quarter valued at approximately $5,992,890,000. International Assets Investment Management LLC grew its position in shares of Eli Lilly and Company by 61,268.8% in the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after purchasing an additional 7,330,815 shares during the last quarter. Sapient Capital LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter worth $682,139,000. Vanguard Group Inc. raised its stake in Eli Lilly and Company by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after purchasing an additional 659,838 shares during the last quarter. Finally, Comerica Bank purchased a new position in shares of Eli Lilly and Company during the third quarter valued at approximately $345,781,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 58,749 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $915.26, for a total value of $53,770,609.74. Following the completion of the transaction, the insider now owns 97,308,620 shares of the company’s stock, valued at $89,062,687,541.20. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, major shareholder Lilly Endowment Inc sold 58,749 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $915.26, for a total transaction of $53,770,609.74. Following the completion of the sale, the insider now directly owns 97,308,620 shares of the company’s stock, valued at approximately $89,062,687,541.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Johna Norton sold 7,056 shares of the stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.38, for a total value of $5,781,545.28. Following the completion of the sale, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The disclosure for this sale can be found here. In the last 90 days, insiders sold 849,894 shares of company stock worth $727,475,118. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Down 0.8 %

NYSE LLY opened at $906.71 on Wednesday. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. Eli Lilly and Company has a 12 month low of $434.34 and a 12 month high of $916.83. The company’s fifty day moving average price is $818.06 and its two-hundred day moving average price is $743.26. The company has a market capitalization of $861.75 billion, a price-to-earnings ratio of 133.54, a price-to-earnings-growth ratio of 1.97 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm’s revenue was up 26.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.62 earnings per share. As a group, research analysts predict that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.57%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on LLY shares. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. BMO Capital Markets raised their target price on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 1st. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Jefferies Financial Group increased their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research note on Monday, June 24th. Finally, Bank of America reissued a “buy” rating and set a $1,000.00 price objective on shares of Eli Lilly and Company in a research note on Monday, June 24th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $812.72.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.